Difference between revisions of "Part:BBa K5121013"
Mdepaulis800 (Talk | contribs) |
Mdepaulis800 (Talk | contribs) |
||
(One intermediate revision by the same user not shown) | |||
Line 5: | Line 5: | ||
<div style="text-align: justify;"> | <div style="text-align: justify;"> | ||
− | == | + | == Background == |
RebA encodes an 18 kDa protein which forms one of the main structural components of type 51 R bodies. This part is based off of the wildtype rebA part — BBa_K2912000 — uploaded by SZU-China in 2019, however has been modified to be compatible with cysteine maleimide conjugation at the N-terminus. This is to allow for conjugation with entire R bodies — note that R bodies should be assembled and purified before conjugation with the constituent rebA monomers. Our team aimed to use conjugation to attach drugs onto R bodies for use in drug delivery. | RebA encodes an 18 kDa protein which forms one of the main structural components of type 51 R bodies. This part is based off of the wildtype rebA part — BBa_K2912000 — uploaded by SZU-China in 2019, however has been modified to be compatible with cysteine maleimide conjugation at the N-terminus. This is to allow for conjugation with entire R bodies — note that R bodies should be assembled and purified before conjugation with the constituent rebA monomers. Our team aimed to use conjugation to attach drugs onto R bodies for use in drug delivery. | ||
Line 25: | Line 25: | ||
<span class='h3bb'><u>Sequence and Features</u></span> | <span class='h3bb'><u>Sequence and Features</u></span> | ||
− | <partinfo> | + | <partinfo>BBa_K5121013 SequenceAndFeatures</partinfo> |
</div> | </div> |
Latest revision as of 12:37, 2 October 2024
rebA N-terminal CGGGGS
Background
RebA encodes an 18 kDa protein which forms one of the main structural components of type 51 R bodies. This part is based off of the wildtype rebA part — BBa_K2912000 — uploaded by SZU-China in 2019, however has been modified to be compatible with cysteine maleimide conjugation at the N-terminus. This is to allow for conjugation with entire R bodies — note that R bodies should be assembled and purified before conjugation with the constituent rebA monomers. Our team aimed to use conjugation to attach drugs onto R bodies for use in drug delivery.
Cysteine maleimide conjugation is a form of Michael addition, in which the thiol of the cysteine acts as a nucleophile to react with maleimide, forming a thiosuccinimide adduct (Figure 1). Through this reaction, drugs with maleimide groups can hence be reacted onto proteins with readily accessible cysteines.
Since wildtype rebA does not have any cysteines (and nor does RebB), maleimide conjugation provides an ideal conjugation method for orthogonal attachment on to R bodies. This part contains an N-terminal cysteine that has been added to facilitate N-terminal conjugation using cysteine maleimide addition. See the design page for more details.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]